It works as a GLP-1 receptor agonist that acts on receptors in the brain and pancreas , which helps regulate appetite, food intake, and blood glucose levels

You should contact your GP if you: Notice any breast changes , including new lumps, thickening, skin dimpling, nipple discharge, or changes in breast shape or sizethese symptoms require urgent assessment and may lead to referral via the NHS two-week suspected cancer pathway (NICE NG12) Have a personal or family history of breast cancer that was not previously discussed when Mounjaro was prescribed Experience unexplained symptoms such as persistent fatigue, unintentional weight loss (beyond expected treatment effects), or other concerning changes Have questions or anxiety about cancer risk that affects your willingness to continue treatment Are due for breast screening and want to discuss whether any additional monitoring is appropriate Your healthcare team can provide personalised risk assessment based on your individual medical history, family history, and other risk factors
At higher doses, it is marketed as Wegovy , specifically for weight management
View our peptide catalog today
(2023)
Mazdutide became the first-ever GLP-1/glucagon dual agonist to receive regulatory approval in June 2025 (China only)